Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Valentina Perrone, Stefania Saragoni, Stefano Buda, Alessandro Broccoli & Luca Degli Esposti. (2016) Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars. Biologics: Targets and Therapy 10, pages 157-165.
Read now
Read now
Holger Schmid. (2013)
Peginesatide for the treatment of renal disease-induced anemia. Expert Opinion on Pharmacotherapy 14:7, pages 937-948.
Read now
Read now
Articles from other publishers (11)
Shinichi Nishi, Masayuki Yamada, Kazuhiko Tsuruya, Ikuto Masakane & Hidetomo Nakamoto. (2019) JR‐131, a Biosimilar of Darbepoetin Alfa, for the Treatment of Hemodialysis Patients With Renal Anemia: A Randomized, Double‐Blinded, Parallel‐Group Phase 3 Study. Therapeutic Apheresis and Dialysis 24:2, pages 126-135.
Crossref
Crossref
Shinichi Nishi, Masayuki Yamada, Kazuhiko Tsuruya, Ikuto Masakane & Hidetomo Nakamoto. (2019) Long‐Term Safety and Efficacy of JR‐131, a Biosimilar of Darbepoetin Alfa, in Japanese Patients With Renal Anemia Undergoing Hemodialysis: Phase 3 Prospective Study. Therapeutic Apheresis and Dialysis 24:2, pages 136-145.
Crossref
Crossref
Piergiorgio Messa & Maria Domenica Cappellini. (2020) A new approach for anemia in kidney disease. European Journal of Internal Medicine 71, pages 1-3.
Crossref
Crossref
Vladimir I. Vaschenko & Vladimir N. Vil’yaninov. (2019) Eryptosis (quasi-apoptosis) the human red blood cells. Its role in medicinal therapy. Reviews on Clinical Pharmacology and Drug Therapy 17:3, pages 5-38.
Crossref
Crossref
Syed M. Qadri, Rosi Bissinger, Ziad Solh & Per-Arne Oldenborg. (2017) Eryptosis in health and disease: A paradigm shift towards understanding the (patho)physiological implications of programmed cell death of erythrocytes. Blood Reviews 31:6, pages 349-361.
Crossref
Crossref
Richard A. Brigandi, Brendan Johnson, Coreen Oei, Mark Westerman, Gordana Olbina, Janak de Zoysa, Simon D. Roger, Manisha Sahay, Nicholas Cross, Lawrence McMahon, Veerabhadra Guptha, Elena A. Smolyarchuk, Narinder Singh, Steven F. Russ, Sanjay Kumar, Alexey V. Borsukov, Vyacheslav V. Marasaev, Gullipalli Prasad, Galina Y. Timokhovskaya, Elena V. Kolmakova, Vladimir A. Dobronravov, Elena V. Zakharova, Georgi Abraham, David Packham, Dmitry A. Zateyshchikov, Gregory P. Arutyunov, Galina V. Volgina, Kirill S. Lipatov, Dmitry V. Perlin, Bruce Cooper, Tarun Kumar Saha, Olga A. Zagrebelnaya, Kalpana S. Mehta, Natalya A. Koziolova, Rob Fassett, Narina P. Alexeeva & Lidia V. Lysenko. (2016) A Novel Hypoxia-Inducible Factor−Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. American Journal of Kidney Diseases 67:6, pages 861-871.
Crossref
Crossref
Francesco Locatelli, Gabriel Choukroun, Matt Truman, Alfons Wiggenhauser & Danilo Fliser. (2016) Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials. Advances in Therapy 33:4, pages 610-625.
Crossref
Crossref
Sarfaraz Niazi. 2015. Biosimilars and Interchangeable Biologics. Biosimilars and Interchangeable Biologics
83
122
.
Paul Wilson & Cheryl Wood. (2015) BIOSIMILAR ESAS: A COMPARATIVE REVIEW. Journal of Renal Care 41:1, pages 53-61.
Crossref
Crossref
I. M. M. van HAELST, A. C. G. EGBERTS, H. J. DOODEMAN, W. W. van SOLINGE, C. J. KALKMAN, M. BENNIS, H. S. TRAAST & W. A. van KLEI. (2012) Occurrence and determinants of poor response to short‐term pre‐operative erythropoietin treatment. Acta Anaesthesiologica Scandinavica 57:3, pages 350-357.
Crossref
Crossref
Ines Jelkmann & Wolfgang Jelkmann. (2013) Impact of Erythropoietin on Intensive Care Unit Patients. Transfusion Medicine and Hemotherapy 40:5, pages 310-318.
Crossref
Crossref